Trial Profile
Retrospective study of pembrolizumab for the treatment of metastatic uveal melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Jan 2018 New trial record